Group 1 - Tyligand Bioscience has submitted its listing application to the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor [3] - The company, founded in 2017, focuses on discovering and developing innovative cancer therapies and currently holds 97 patents and patent applications, including 25 related to its core product TSN1611 [4] - Tyligand Bioscience has not yet received any market approval for its candidate drugs and has not generated any revenue from product sales [4] Group 2 - As of December 31, 2023, the company reported revenues of 7.856 million RMB, 1.506 million RMB for the nine months ending September 30, 2024, and 11.358 million RMB for the first nine months of 2025 [7] - The company incurred losses of 70.461 million RMB, 28.354 million RMB, and 123.406 million RMB for the respective periods [7] - Revenue sources include providing research and development services and intellectual property licensing [7]
泰励生物尚未盈利赴港IPO，美籍华人CEO张博士师从诺贝尔化学奖得主
Sou Hu Cai Jing·2026-01-30 09:48